Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.
The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA.
Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels.
It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer.
It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 24 | 3.96 Decreased by -0.50% | 3.87 Increased by +2.33% |
| Mar 5, 24 | 4.40 Increased by +7.58% | 4.30 Increased by +2.33% |
| Oct 31, 23 | 4.96 Increased by +5.53% | 4.67 Increased by +6.21% |
| Aug 3, 23 | 5.00 Increased by +7.53% | 4.49 Increased by +11.36% |
| Apr 27, 23 | 3.98 Decreased by -6.35% | 3.85 Increased by +3.38% |
| Jan 31, 23 | 4.09 Decreased by -6.19% | 4.10 Decreased by -0.24% |
| Nov 3, 22 | 4.70 Increased by +0.64% | 4.44 Increased by +5.86% |
| Aug 4, 22 | 4.65 Increased by +6.16% | 4.40 Increased by +5.68% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 6.90 B Increased by +3.77% | 1.73 B Decreased by -19.27% | Increased by +25.06% Decreased by -22.21% |
| Jun 30, 23 | 6.99 B Increased by +5.94% | 1.38 B Increased by +4.71% | Increased by +19.74% Decreased by -1.17% |
| Mar 31, 23 | 6.11 B Decreased by -2.13% | 2.84 B Increased by +92.48% | Increased by +46.54% Increased by +96.67% |
| Dec 31, 22 | 6.84 B Decreased by -0.10% | 1.62 B Decreased by -14.90% | Increased by +23.63% Decreased by -14.82% |
| Sep 30, 22 | 6.65 B Decreased by -0.81% | 2.14 B Increased by +13.75% | Increased by +32.22% Increased by +14.67% |
| Jun 30, 22 | 6.59 B Increased by +1.04% | 1.32 B Increased by +183.84% | Increased by +19.97% Increased by +180.91% |
| Mar 31, 22 | 6.24 B Increased by +5.71% | 1.48 B Decreased by -10.33% | Increased by +23.66% Decreased by -15.17% |
| Dec 31, 21 | 6.85 B Increased by +3.20% | 1.90 B Increased by +17.59% | Increased by +27.74% Increased by +13.94% |